Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGC NASDAQ:IMMX NASDAQ:SLRN NASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGCCanopy Growth$1.40-6.0%$1.27$0.77▼$5.80$357.38M0.7729.99 million shs21.62 million shsIMMXImmix Biopharma$2.22-2.6%$2.49$1.26▼$3.20$64.01M0.25257,757 shs56,780 shsSLRNAcelyrin$2.27$2.27$1.85▼$7.10$229.17M1.071.29 million shsN/ATVGNTevogen Bio$0.89$1.06$0.26▼$3.09$175.07M-0.781.43 million shs324,097 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGCCanopy Growth-6.04%-7.28%+27.27%+2.19%-72.22%IMMXImmix Biopharma-2.63%+13.27%-12.60%+1.37%+8.82%SLRNAcelyrin0.00%0.00%0.00%0.00%-50.33%TVGNTevogen Bio0.00%-3.25%-10.34%-36.88%+88.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGCCanopy Growth1.4075 of 5 stars0.04.00.00.03.90.81.3IMMXImmix Biopharma3.1802 of 5 stars3.35.00.00.01.03.30.6SLRNAcelyrin2.1717 of 5 stars3.20.00.00.00.62.51.3TVGNTevogen Bio3.3853 of 5 stars3.52.00.00.02.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGCCanopy Growth 1.33SellN/AN/AIMMXImmix Biopharma 2.50Moderate Buy$7.00215.32% UpsideSLRNAcelyrin 2.33Hold$7.33223.05% UpsideTVGNTevogen Bio 3.00Buy$10.001,023.60% UpsideCurrent Analyst Ratings BreakdownLatest IMMX, TVGN, SLRN, and CGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025IMMXImmix BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/18/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.008/12/2025CGCCanopy GrowthZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/4/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/18/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/10/2025TVGNTevogen BioD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/4/2025IMMXImmix BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGCCanopy Growth$274.92M1.22N/AN/A$1.47 per share0.95IMMXImmix BiopharmaN/AN/AN/AN/A$0.16 per shareN/ASLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/ATVGNTevogen BioN/AN/AN/AN/A($0.09) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGCCanopy Growth-$429.86M-$3.03N/AN/AN/A-155.76%-89.93%-44.24%11/14/2025 (Estimated)IMMXImmix Biopharma-$21.61M-$0.77N/AN/AN/AN/A-205.35%-110.63%11/11/2025 (Estimated)SLRNAcelyrin-$381.64M-$2.69N/AN/AN/AN/A-44.12%-39.02%N/ATVGNTevogen Bio-$13.73MN/A0.00∞N/AN/AN/A-775.49%11/10/2025 (Estimated)Latest IMMX, TVGN, SLRN, and CGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025N/ATVGNTevogen Bio-$0.05-$0.03+$0.02-$0.03N/AN/A8/8/2025Q1 2026CGCCanopy Growth-$0.15-$0.14+$0.01-$0.16$64.98 million$52.98 million8/8/2025Q1 2025IMMXImmix Biopharma-$0.21-$0.22-$0.01-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGCCanopy GrowthN/AN/AN/AN/AN/AIMMXImmix BiopharmaN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGCCanopy Growth0.593.072.12IMMXImmix BiopharmaN/A1.231.23SLRNAcelyrinN/A7.157.15TVGNTevogen BioN/A0.260.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGCCanopy Growth3.33%IMMXImmix Biopharma11.26%SLRNAcelyrin87.31%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipCGCCanopy Growth0.16%IMMXImmix Biopharma55.40%SLRNAcelyrin13.60%TVGNTevogen Bio73.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGCCanopy Growth3,150239.85 million239.47 millionOptionableIMMXImmix Biopharma928.83 million12.86 millionOptionableSLRNAcelyrin135100.95 million86.68 millionOptionableTVGNTevogen Bio3196.71 million52.64 millionN/AIMMX, TVGN, SLRN, and CGC HeadlinesRecent News About These CompaniesTevogen Bio Highlights Promising Clinical Results for TVGN 489 in Treating SARS-CoV-2 in Immunocompromised PatientsSeptember 3 at 4:31 PM | quiverquant.comQTevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2September 3 at 4:15 PM | globenewswire.comTevogen Bio Inc: Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureAugust 28, 2025 | finanznachrichten.deTevogen Bio Holdings Inc. Highlights Internally Developed Assets Reflecting Long-Term ValueAugust 27, 2025 | quiverquant.comQTevogen Bio Highlights Proprietary Assets and Upcoming Valuation DisclosureAugust 27, 2025 | globenewswire.comTevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health EquityAugust 26, 2025 | markets.businessinsider.comTevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health EquityAugust 26, 2025 | globenewswire.comTevogen Bio Holdings Inc. Reports 24% Increase in Institutional Ownership in Q2 2025August 25, 2025 | quiverquant.comQTevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained PositionsAugust 25, 2025 | globenewswire.comTevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable BiopharmaAugust 22, 2025 | markets.businessinsider.comTevogen Bio Holdings Inc. Recognized in BINJE's BEST Health Care 2025 for Commitment to Health Equity and InnovationAugust 22, 2025 | quiverquant.comQTevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable BiopharmaAugust 22, 2025 | globenewswire.comTevogen Bio (NASDAQ:TVGN) Announces Earnings ResultsAugust 21, 2025 | marketbeat.comD. Boral Capital Reiterates Buy Rating for Tevogen Bio (NASDAQ:TVGN)August 20, 2025 | marketbeat.comTevogen finalizes agreement for up to $50M in financingAugust 19, 2025 | msn.comREPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance ...August 19, 2025 | bakersfield.comBREPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development EffortsAugust 19, 2025 | globenewswire.comTevogen Bio Holdings Inc. Reports Q2 2025 Financial Results with Reduced Loss from Operations and Focus on Growth StrategyAugust 19, 2025 | quiverquant.comQTevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth MomentumAugust 19, 2025 | globenewswire.comTevogen CEO Donates Personal Shares to Support Local Law EnforcementAugust 18, 2025 | globenewswire.comTevogen CEO Donates Personal Shares to Support Brain Injury RecoveryAugust 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMMX, TVGN, SLRN, and CGC Company DescriptionsCanopy Growth NASDAQ:CGC$1.40 -0.09 (-6.04%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.39 -0.01 (-0.43%) As of 09/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Immix Biopharma NASDAQ:IMMX$2.22 -0.06 (-2.63%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$2.22 0.00 (0.00%) As of 09/3/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.Acelyrin NASDAQ:SLRNAcelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Tevogen Bio NASDAQ:TVGN$0.89 0.00 (0.00%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$0.90 +0.01 (+1.46%) As of 09/3/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
